Market Overview - The Hong Kong stock market showed a rebound after an initial decline, with the Hang Seng Index closing up 0.14% at 26,885.24 points, the Hang Seng Tech Index up 0.74% at 5,406.13 points, and the China Enterprises Index up 0.50% at 9,093.34 points. Southbound funds recorded a net inflow of over 22 billion HKD [1] - Major technology stocks, including Xiaomi and Baidu, saw gains of nearly 3%, while Meituan rose nearly 2%. Other sectors such as restaurants, dairy, and beer stocks also performed well, indicating a recovery in industry operations [1] Company Highlights - Yurun Dairy (09858) rose nearly 5% after announcing a share placement to raise approximately 2.33 billion HKD (about 2.07 billion RMB), primarily from its major shareholder, Yili, increasing its stake from 33.93% to 36.07% [2] - Baidu Group (09888) increased by over 3% following the announcement of a new stock buyback plan with a maximum amount of 5 billion USD, effective until December 31, 2028, and the approval of a dividend policy expected to be announced in 2026 [2] - Xindong Company (02400) saw a rise of nearly 5% due to the launch of its AI game creation product "Taptap Maker," which is expected to lower development barriers in the gaming industry [2] - CloudTop New Horizon (01952) gained over 4% after signing an exclusive commercialization agreement for a new peptide drug, strengthening its position in the Asian market for kidney and autoimmune diseases [3] - Mao Geping (01318) rose over 5% as it climbed to the 4th position in the Douyin beauty rankings, indicating strong brand performance [3] - Horizon Robotics (09660) increased by over 3% after being recognized as a market leader in the ADAS sector with a 47.66% market share [4] Investment Insights - BNP Paribas maintains a positive outlook on the Chinese stock market, expecting no significant impact from the recent appreciation of the RMB on equity returns, valuations, and stock performance [6] - Huatai Securities emphasizes the importance of mid-term perspectives, suggesting that the current market sentiment is optimistic, with key drivers for the first quarter being liquidity improvement and enhanced profit expectations [7] - CCB International remains bullish on H-shares in the banking sector, noting that the average price-to-book ratio is at a historical low, making it attractive for long-term investors [8] - CICC forecasts a mild recovery in the consumer building materials sector, with leading companies expected to improve margins due to recent price increases in various sub-sectors [9]

Industry Updates - The Ministry of Finance, General Administration of Customs, and State Taxation Administration jointly announced a policy allowing residents of Hainan Free Trade Port to purchase imported goods at "zero tariffs," with a tax exemption limit of 10,000 RMB per person per year and no limit on purchase frequency [1] - The State Administration for Market Regulation is intensifying efforts to combat issues in live-streaming e-commerce, focusing on counterfeit goods and false marketing, and has initiated a special rectification campaign [1] - The Ministry of Industry and Information Technology has prioritized addressing the internal competition in the photovoltaic industry, aiming to achieve a dynamic balance between supply and demand through enhanced departmental collaboration [1] - Anhui Province has set a regional GDP growth target of 5% to 5.5% for 2026 [1] - The Internationally first and largest single-unit power compressed air energy storage compressor, developed by the Institute of Engineering Thermophysics of the Chinese Academy of Sciences and China Storage Energy (Beijing) Technology Co., has passed third-party testing with CNAS accreditation, reaching an internationally leading level [1] Company Updates - Kweichow Moutai responded to issues with the iMoutai App, stating that recent high demand and a surge in orders have led to difficulties in app loading and customer service line congestion [1] - Tesla's energy super factory has begun supplying capacity to multiple domestic and international markets [1] - Foxconn's new energy vehicle R&D center officially commenced operations on February 4 in Zhengzhou Airport, focusing on next-generation electronic and electrical architecture and smart driving technologies [1] - NewEase has announced that its 1.6T optical module products have achieved mass delivery and are in the process of continuous capacity enhancement [1] - Lei Jun announced via Weibo that the next-generation SU7 is expected to launch in April 2026, with pre-orders now open [1] - Yunding Xinyao signed an exclusive commercialization licensing agreement with Macao Teo, obtaining exclusive commercialization rights for MT1013 in China and the Asia-Pacific region (excluding Japan) [1] - Changan Automobile, in collaboration with CATL, is introducing sodium-ion batteries, planning to implement them in multiple models by 2026 [1]

每经AI快讯，云顶新耀(01952.HK)涨超4%，截至发稿涨4.03%，报39.22港元，成交额8486.66万港元。 （文章来源：每日经济新闻） ...

另一方面，通过引入MT1013这一临床后期创新资产，云顶新耀也将进一步丰富肾科管线梯队，构建起 兼具短期收益、中期增长与长期潜力的可持续管线体系。根据协议，云顶新耀将向麦科奥特支付人民币 2亿元首付款，以及最高不超过人民币10.40亿元的潜在监管及商业里程碑付款。目前，MT1013中国III 期临床研究正在进行中，相关临床开发费用将由麦科奥特承担。 智通财经APP获悉，云顶新耀(01952)涨超4%，截至发稿，涨4.03%，报39.22港元，成交额8486.66万港 元。 消息面上，2月5日，云顶新耀宣布与麦科奥特签署独家商业化许可协议，获得全球首创双靶点多肽新药 MT1013在中国及亚太区(日本除外)的独家商业化授权。此次合作标志着云顶新耀肾科战略由聚焦单一 疾病领域向系统化和平台化的发展阶段升级，MT1013将与云顶新耀现有肾科管线形成协同效应，强化 产品布局，巩固公司在亚洲肾脏及自身免疫疾病领域的领导地位，并将产品覆盖从IgA肾病拓展至更广 泛的慢性肾脏病领域。 ...

云顶新耀(01952)涨超4%，截至发稿，涨4.03%，报39.22港元，成交额8486.66万港元。 消息面上，2月5日，云顶新耀宣布与麦科奥特签署独家商业化许可协议，获得全球首创双靶点多肽新药 MT1013在中国及亚太区(日本除外)的独家商业化授权。此次合作标志着云顶新耀肾科战略由聚焦单一 疾病领域向系统化和平台化的发展阶段升级，MT1013将与云顶新耀现有肾科管线形成协同效应，强化 产品布局，巩固公司在亚洲肾脏及自身免疫疾病领域的领导地位，并将产品覆盖从IgA肾病拓展至更广 泛的慢性肾脏病领域。 另一方面，通过引入MT1013这一临床后期创新资产，云顶新耀也将进一步丰富肾科管线梯队，构建起 兼具短期收益、中期增长与长期潜力的可持续管线体系。根据协议，云顶新耀将向麦科奥特支付人民币 2亿元首付款，以及最高不超过人民币10.40亿元的潜在监管及商业里程碑付款。目前，MT1013中国III 期临床研究正在进行中，相关临床开发费用将由麦科奥特承担。 ...

此前，云顶新耀已凭借全球首个IgA肾病对因治疗药物耐赋康在肾病治疗领域崭露头角。该公司财务数据显示，2025年前 三季度，耐赋康的销售额突破10亿元。云顶新耀方面表示："耐赋康的成功，不仅验证了云顶新耀在肾科领域的渠道覆盖与学 术推广能力，更依托于云顶新耀搭建起的以科学和商业洞察为基础的'准入、医学、市场、销售'（A2MS）一体化的商业化运 营平台。MT1013的加入，将与云顶新耀现有的肾科产品组合形成高度协同，推动公司肾科布局从覆盖IgA肾病拓展至更广泛的 慢性肾脏病，进一步完善肾科产品矩阵，夯实其在肾科领域的布局优势。" 对于此次合作，云顶新耀董事会主席吴以芳表示："在全球慢性肾脏病患者持续增加的背景下，继发性甲状旁腺功能亢进 仍存在显著临床未满足需求。MT1013作为具备全球首创双重作用机制的临床后期创新资产，有望为SHPT患者提供全新的治疗 选择。作为潜在同类最佳药物，MT1013将与公司现有的肾科产品组合形成高度协同，进一步夯实公司在肾科领域的布局。云 顶新耀在持续深耕自身免疫相关肾脏疾病的基础上，正加速拓展至肾小球肾炎以及慢性肾脏病及其并发症等更广泛的治疗领 域。此次合作是公司完善创新管线、拓展肾 ...

2月5日，云顶新耀发布公告称，与陕西麦科奥特医药科技股份有限公司（以下简称"麦科奥特"）签署独 家商业化许可协议，获得MT1013在中国及亚太区（日本除外）的独家商业化授权。MT1013为全球首创 的双靶点受体激动剂多肽，可同时靶向钙敏感受体(CaSR)及成骨生长肽(OGP)受体，开发主要用于治疗 继发性甲状旁腺功能亢进症(SHPT)。此次战略合作将与云顶新耀现有肾科管线形成协同效应，强化产 品布局，巩固公司在亚洲肾脏及自身免疫疾病领域的领导地位，并将产品覆盖从IgA肾病拓展至更广泛 的慢性肾脏病领域。 根据协议，云顶新耀将向麦科奥特支付人民币2亿元首付款，以及最高不超过人民币10.40亿元的潜在监 管及商业里程碑付款。中国III期临床研究正在进行中，相关临床开发费用将由麦科奥特承担。 ...

Market Overview - The Hang Seng Index is expected to hold at 26,000 points, influenced by the hawkish stance of the newly appointed Federal Reserve Chairman and a rebound in the US dollar index, which has led to market adjustments in commodities [2] - The Chinese GDP growth target for 2026 is anticipated to be set between 4.5% and 5%, lower than the previous target of around 5% for 2025, as local governments have begun to lower their GDP targets ahead of the Two Sessions [2] - Regulatory measures have been implemented to cool the market, including increased financing margin ratios on the Shanghai and Shenzhen stock exchanges, which has led to a collective reduction in leverage across the three markets [2] Sector Focus - Macau gaming stocks are favored in the short term due to January's gambling revenue exceeding expectations, with the upcoming Spring Festival serving as a catalyst for growth [3] Macro Focus - China's January RatingDog services PMI rose to 52.3, indicating an acceleration in service sector expansion, with new export orders showing strong growth [7] - The People's Bank of China emphasizes the need to support domestic demand and technological innovation in its 2026 credit market work [7] - The US ADP reported a lower-than-expected increase of 22,000 private sector jobs in January, indicating potential labor market weaknesses [7] Company News - Walden Materials (9981) is launching an IPO to raise approximately HKD 28 billion, with a share price capped at HKD 20.09 [9] - Baidu Group (9888) plans to repurchase USD 5 billion in shares and will announce its first dividend this year [9] - Meituan (3690) and Tencent (0700) are taking measures to regulate promotional activities on their platforms, reflecting a tightening of marketing practices [9] - BYD (1211) reported a tenfold increase in electric vehicle sales in Germany, significantly outperforming Tesla [9] - Tesla (TSLA.US) saw a 9.3% increase in electric vehicle sales in China but a 57% drop in the UK market [9]

2月5日，港股创新药企云顶新耀(01952)宣布，与麦科奥特签署独家商业化许可协议，获得全球首创双 靶点多肽新药MT1013在中国及亚太区(日本除外)的独家商业化授权。此次合作标志着云顶新耀肾科战 略由聚焦单一疾病领域向系统化和平台化的发展阶段升级，MT1013将与云顶新耀现有肾科管线形成协 同效应，强化产品布局，巩固公司在亚洲肾脏及自身免疫疾病领域的领导地位，并将产品覆盖从IgA肾 病拓展至更广泛的慢性肾脏病领域。 根据协议，云顶新耀将向麦科奥特支付人民币2亿元首付款，以及最高不超过人民币10.40亿元的潜在监 管及商业里程碑付款。中国III期临床研究正在进行中，相关临床开发费用将由麦科奥特承担。 通过引入MT1013这一临床后期创新资产，云顶新耀也将进一步丰富肾科管线梯队，构建起兼具短期收 益、中期增长与长期潜力的可持续管线体系，为公司长期稳健发展筑牢根基。 对于此次合作，云顶新耀董事会主席吴以芳表示："在全球慢性肾脏病患者持续增加的背景下，继发性 甲状旁腺功能亢进仍存在显著临床未满足需求。MT1013作为具备全球首创双重作用机制的临床后期创 新资产，有望为SHPT患者提供全新的治疗选择。此次合作是公司完 ...

据了解，继发性甲状旁腺功能亢进(SHPT)是慢性肾脏病(CKD)患者最常见的严重并发症之一，该疾病导 致钙磷代谢紊乱、甲状旁腺激素升高、骨病变、血管钙化等一系列病理变化，显著增加骨折、心血管事 件和死亡风险，是影响CKD患者预后的关键因素。 MT1013是由麦科奥特自主研发的全球首创双靶点多肽新药，2025年获美国肾脏病学会(ASN)年会"Late- Breaking"收录。MT1013其开创性地融合了"钙敏感受体(CaSR)+成骨生长肽(OGP)模拟"双重作用机制， 解决了PTH、钙、磷代谢平衡的问题。这一全新设计使其在治疗SHPT及相关骨代谢疾病时，首次创造 性的从源头上控制病情，且能通过直接激活成骨通路，主动促进骨形成与修复，实现从"间接抑制骨吸 收"到"主动促进骨生成"的治疗创新升级。此外，MT1013还计划拓展至包括慢性肾病性矿物质和骨代谢 异常(CKD-MBD)伴骨质疏松及未接受透析的SHPT在内的额外适应症。 目前，全球慢性肾脏病(CKD)患者人数已从2019年的9.052亿增至2024年的10.655亿，预计2030年超12 亿、2035年超15亿;同期SHPT患者预计2030年达1.899亿 ...